Bristol-Myers Squibb Co (BMY) Shares Bought by First Hawaiian Bank

First Hawaiian Bank boosted its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 16.6% in the 4th quarter, Holdings Channel reports. The firm owned 34,919 shares of the biopharmaceutical company’s stock after buying an additional 4,984 shares during the quarter. First Hawaiian Bank’s holdings in Bristol-Myers Squibb were worth $1,816,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Arlington Partners LLC raised its stake in Bristol-Myers Squibb by 40.0% during the 4th quarter. Arlington Partners LLC now owns 1,400 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 400 shares during the last quarter. Cypress Capital Management LLC WY raised its stake in shares of Bristol-Myers Squibb by 154.7% in the 3rd quarter. Cypress Capital Management LLC WY now owns 1,910 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 1,160 shares in the last quarter. CLS Investments LLC raised its stake in shares of Bristol-Myers Squibb by 194.3% in the 3rd quarter. CLS Investments LLC now owns 2,575 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 1,700 shares in the last quarter. Highwater Wealth Management LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $170,000. Finally, Selective Wealth Management acquired a new position in shares of Bristol-Myers Squibb in the 3rd quarter valued at $184,000. Hedge funds and other institutional investors own 72.68% of the company’s stock.

BMY opened at $47.99 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.40 and a current ratio of 1.53. Bristol-Myers Squibb Co has a twelve month low of $44.30 and a twelve month high of $70.05. The stock has a market capitalization of $77.01 billion, a PE ratio of 15.94, a PEG ratio of 1.29 and a beta of 0.98.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.91 by $0.18. Bristol-Myers Squibb had a net margin of 6.50% and a return on equity of 47.89%. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Analysts expect that Bristol-Myers Squibb Co will post 3.88 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, February 1st. Stockholders of record on Friday, January 4th will be issued a $0.41 dividend. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. The ex-dividend date is Thursday, January 3rd. This represents a $1.64 annualized dividend and a dividend yield of 3.42%. Bristol-Myers Squibb’s dividend payout ratio is presently 54.49%.

A number of brokerages have recently issued reports on BMY. Guggenheim began coverage on shares of Bristol-Myers Squibb in a research note on Monday, October 8th. They issued a “neutral” rating for the company. JPMorgan Chase & Co. increased their price objective on shares of Bristol-Myers Squibb from $70.00 to $74.00 and gave the company an “overweight” rating in a research note on Monday, October 8th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $70.00 price objective for the company in a research note on Friday, October 5th. Credit Suisse Group set a $61.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Sunday, October 14th. Finally, Barclays increased their price objective on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the company an “equal weight” rating in a research note on Friday, October 12th. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $61.56.

TRADEMARK VIOLATION WARNING: “Bristol-Myers Squibb Co (BMY) Shares Bought by First Hawaiian Bank” was originally posted by WKRB News and is owned by of WKRB News. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.wkrb13.com/2019/01/12/bristol-myers-squibb-co-bmy-shares-bought-by-first-hawaiian-bank.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Featured Story: How to calculate the annual rate of depreciation

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply